申请人:Pfizer Inc
公开号:US06340681B1
公开(公告)日:2002-01-22
A compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein
R1 and R2 are independently selected from hydrogen, halo, hydroxy, (C1-C4)alkyl, halo (C1-C4)alkyl and the like; R3 and R4 are independently selected from hydrogen, halo(C1-C10)alkyl, optionally substituted (C1-C6)alkyl and the like, or R3 and R4, together with the nitrogen atom to which they are attached, form an optionally substituted fully saturated, partially saturated or fully unsaturated heterocyclic ring; and R5 is (C4-C11)cycloalkyl and the like, has ORL1-receptor agonist activity, and are useful as analgesics or the like in mammalian subjects.
该化合物的结构式为:或其药用可接受的盐,其中R1和R2独立选择自氢、卤素、羟基、(C1-C4)烷基、卤代(C1-C4)烷基等;R3和R4独立选择自氢、卤代(C1-C10)烷基、可选择取代的(C1-C6)烷基等,或者R3和R4与它们连接的氮原子一起形成一个可选择取代的完全饱和、部分饱和或完全不饱和的杂环环;R5为(C4-C11)环烷基等,具有ORL1受体激动剂活性,并且在哺乳动物体内可用作镇痛剂或类似物。